Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ABBV AbbVie Inc

Price (delayed)

$195

Market cap

$344.45B

P/E Ratio

82.63

Dividend/share

$6.38

EPS

$2.36

Enterprise value

$409.16B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate ...

Highlights
ABBV's gross profit is up by 20% year-on-year and by 2.9% since the previous quarter
The gross margin has grown by 13% YoY
The quick ratio has contracted by 33% YoY but it has grown by 12% from the previous quarter
The debt has declined by 6% year-on-year but it rose by 4.1% since the previous quarter
ABBV's P/E is 105% above its 5-year quarterly average of 40.3 and 15% above its last 4 quarters average of 72.1
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter

Key stats

What are the main financial stats of ABBV
Market
Shares outstanding
1.77B
Market cap
$344.45B
Enterprise value
$409.16B
Valuations
Price to earnings (P/E)
82.63
Price to book (P/B)
242.43
Price to sales (P/S)
6.01
EV/EBIT
68.79
EV/EBITDA
28.61
EV/Sales
7.13
Earnings
Revenue
$57.37B
Gross profit
$40.56B
Operating income
$10.07B
Net income
$4.2B
EBIT
$5.95B
EBITDA
$14.3B
Free cash flow
$15.39B
Per share
EPS
$2.36
EPS diluted
$2.35
Free cash flow per share
$8.7
Book value per share
$0.8
Revenue per share
$32.45
TBVPS
$23.98
Balance sheet
Total assets
$136.17B
Total liabilities
$134.7B
Debt
$69.89B
Equity
$1.42B
Working capital
-$8.73B
Liquidity
Debt to equity
49.22
Current ratio
0.76
Quick ratio
0.48
Net debt/EBITDA
4.53
Margins
EBITDA margin
24.9%
Gross margin
70.7%
Net margin
7.3%
Operating margin
17.6%
Efficiency
Return on assets
3%
Return on equity
95.6%
Return on invested capital
9.2%
Return on capital employed
6%
Return on sales
10.4%
Dividend
Dividend yield
3.27%
DPS
$6.38
Payout ratio
270.3%

ABBV stock price

How has the AbbVie stock price performed over time
Intraday
2.3%
1 week
3.02%
1 month
2.9%
1 year
15.97%
YTD
9.74%
QTD
5.05%

Financial performance

How have AbbVie's revenue and profit performed over time
Revenue
$57.37B
Gross profit
$40.56B
Operating income
$10.07B
Net income
$4.2B
Gross margin
70.7%
Net margin
7.3%

ABBV financials

The net margin has declined by 34% year-on-year and by 3.9% since the previous quarter
The company's net income fell by 30% YoY
The operating margin has declined by 25% year-on-year but it rose by 9% since the previous quarter
The operating income has contracted by 21% YoY but it has grown by 10% from the previous quarter

Price vs fundamentals

How does ABBV's price correlate with its fundamentals

ABBV Price vs fundamentals

ABBV Earnings waterfall

ABBV Price vs fair value

Growth

What is AbbVie's growth rate over time

ABBV growth chart

Valuation

What is AbbVie stock price valuation
P/E
82.63
P/B
242.43
P/S
6.01
EV/EBIT
68.79
EV/EBITDA
28.61
EV/Sales
7.13

Valuation vs average

Price to earnings (P/E)

ABBV's P/E is 105% above its 5-year quarterly average of 40.3 and 15% above its last 4 quarters average of 72.1
The EPS has contracted by 30% YoY

Price to book (P/B)

ABBV's price to book (P/B) is 112% higher than its last 4 quarters average of 114.4
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter

Price to sales (P/S)

ABBV's P/S is 25% above its 5-year quarterly average of 4.8
ABBV's revenue is up by 5% year-on-year

Efficiency

How efficient is AbbVie business performance
The ROE has soared by 73% YoY and by 35% from the previous quarter
AbbVie's ROIC has decreased by 39% YoY
The ROS has contracted by 38% YoY
AbbVie's return on assets has decreased by 30% YoY

Dividends

What is ABBV's dividend history
DPS
$6.38
Dividend yield
3.27%
Payout ratio
270.3%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did AbbVie financials performed over time

Assets vs liabilities

The quick ratio has contracted by 33% YoY but it has grown by 12% from the previous quarter
ABBV's current ratio is down by 19% year-on-year but it is up by 15% since the previous quarter

Debt vs equity

The company's debt to equity has surged by 144% QoQ
AbbVie's equity has plunged by 82% YoY and by 57% from the previous quarter

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.